植物来源天然产物靶向炎症治疗动脉粥样硬化
本综述系统分析10种植物及23种高潜力代谢物(如丹参酮IIA、小檗碱、人参皂苷Rb1),发现抗AS天然产物主要来自五加科、伞形科、豆科和唇形科,化学结构以黄酮、生物碱、皂苷和多糖为主。抗炎通路集中在抑制NF-κB/NLRP3炎症小体、清除ROS和保护内皮,并强调NLRP3抑制与肠道菌群调节为新方向。
要点
- 抗AS天然产物多来自五加科、伞形科、豆科和唇形科植物。
- 黄酮、生物碱和皂苷类结构抗AS潜力较大。
- 抑制NF-κB/NLRP3炎症小体是核心抗炎机制之一。
核心结论
- 植物来源天然产物通过多靶点抗炎机制在动脉粥样硬化治疗中具有潜力。
- NLRP3炎症小体抑制和肠道菌群调节是新兴治疗途径。
研究设计与样本
- 综述系统分析10种植物物种,聚焦23种高潜力代谢物,包括丹参酮IIA、小檗碱和人参皂苷Rb1等。
主要发现
- 抗AS天然产物主要来自五加科、伞形科、豆科和唇形科植物。
- 化学结构主要为黄酮、生物碱、皂苷和多糖等。
- 不同结构类型均可显示抗AS活性,其中黄酮、生物碱和皂苷潜力较大。
- 主要抗炎通路包括抑制NF-κB/NLRP3炎症小体(如丹参酮IIA、红景天苷)、清除ROS(如丹参素、迷迭香酸)和保护内皮(如黄芪甲苷、葛根素)。
临床怎么用
- 可关注丹参酮IIA、小檗碱、人参皂苷Rb1等天然产物在抗AS抗炎治疗中的潜在应用。
- 临床可重视抑制NF-κB/NLRP3炎症小体、清除ROS和保护内皮等抗炎通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atherosclerosis (AS) is a complex and chronic inflammatory vascular disease, and it's also the pathological basis of various diseases such as coronary heart disease. Owing to their advantages such as multiple targets and rich diversity, Plant-Derived natural products with abundant resources will become an important source of anti-AS drugs. Herein, we explored the intricate association between inflammation and AS, focusing on plant-derived natural products that specifically target inflammation for the treatment of AS. This review systematically analyzes 10 plant species, focusing on 23 high-potential metabolites including Tanshinone IIA, Berberine, and Ginsenoside Rb1 et al. We found that natural products with anti-AS properties are primarily derived from plants belonging to the families Araliaceae, Umbelliferae, Fabaceae, and Lamiaceae. The chemical structures of these natural products mainly consist of flavonoids, alkaloids, saponins, and polysaccharides, among others. This suggests that natural products with different structural types can exhibit anti-AS activities, with flavonoids, alkaloids, and saponins showing greater potential. Major anti-inflammatory pathways center on NF-κB/NLRP3 inflammasome inhibition (e.g., Tan IIA, Salidroside), ROS scavenging (e.g., Danshensu, Rosmarinic acid), and endothelial protection (e.g., Astragaloside, Puerarin), while highlighting NLRP3 inflammasome inhibition and gut-microbiota modulation as emerging therapeutic avenues. These will actively promote the clinical application and industrial production of Plant Derived natural products, thereby developing anti AS drugs with excellent efficacy and reduced adverse reactions. We hope that this comprehensive review will provide valuable insights into the potential and pharmacological mechanisms of current natural medicines, thereby offering support for future drug discoveries.
引用
- Hua Z, Wang X, Qin LL, et al. Plant-derived natural products targeting inflammation in treatment of atherosclerosis. Front Pharmacol. 2025. PMID: 41111503. doi:10.3389/fphar.2025.1642183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。